Abstract
Zirconium-89 (89Zr) is a long-lived (t1/2 = 78.4 h) positron-emitting isotope that is useful for positron emission tomography (PET) based diagnostic imaging using radiolabeled antibodies. Hydroxamate resin columns are predominantly used for the purification of 89Zr from cyclotron bombarded natY targets dissolved in strong HCl. 89Zr is conventionally eluted from the resin in 1 M oxalic acid (H2C2O4), a complexant that is conducive to follow-on binding of 89Zr through a transchelation process to the deferoxamine siderophore. In the present study, we determined that a lower concentration of H2C2O4 eluent (0.8 M) is adequate to efficiently remove 89Zr from a column containing 100 mg hydroxamate resin. As a result, less buffering agents are needed to be added to the 89Zr product fraction prior to labeling. A simple automated fluidic system prototype has been developed to perform the steps required for 89Zr purification using a hydroxamate resin column (column conditioning in HCl, Y target dissolution, dissolved target solution load onto column, column washes using HCl and water, and 89Zr elution). The system performance was evaluated using several cyclotron bombarded Y targets; 89Zr product fractions demonstrated excellent chemical recoveries from these targets, with 1.0 mL product volumes yielding 89±2% of the column elution peak activity and 84±2% of 89Zr recovered from the target (at EOB). These results compare favorably with previously published 89Zr product volumes and yields, despite the lower concentration of H2C2O4 eluent employed. Transchelation of resulting 89Zr product fractions was performed to assess product quality. The effective specific activity (ESA) ranged between 44(7) and 109(22) TBq·mmole-1, while the bindable metals concentration, a metric introduced for assessing and comparing product purity, ranged between 43(7) and 115(27) nmole·g-1.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 85-94 |
| Number of pages | 10 |
| Journal | Applied Radiation and Isotopes |
| Volume | 132 |
| DOIs | |
| State | Published - Feb 1 2018 |
Funding
This work was funded by the U.S. Department of Energy Office of Science , Isotope Development and Production for Research and Applications ( IDPRA ) subprogram of the Office of Nuclear Physics ( Field Work Proposal 61059 ). The Pacific Northwest National Laboratory is operated for the U.S. Department of Energy by Battelle under contract DE-AC06-67RLO 1830 . The CTI Eclipse/111 cyclotron at the University of Washington is supported by the National Institute of Health ( S10-RR017229 ). The authors would like to acknowledge Marvin G. Warner and Forrest A. Laskowski (PNNL) for synthesis of the hydroxamate resin, and Kenneth A. Krohn (Oregon Health and Science University/University of Washington) for helpful discussions.
| Funders | Funder number |
|---|---|
| Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health | S10-RR017229 |
| U.S. Department of Energy | |
| Battelle | DE-AC06-67RLO 1830 |
| Sicilian Center of Nuclear Physics and Physics of Matter | 61059 |
Keywords
- Deferoxamine
- Hydroxamate
- ImmunoPET
- Laboratory automation
- Medical isotope
- Zirconium-89
- Zr
ASJC Scopus subject areas
- Radiation
Fingerprint
Dive into the research topics of 'Hydroxamate column-based purification of zirconium-89 (89Zr) using an automated fluidic platform'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS